Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Apellis Pharmaceuticals reported a strong turnaround for the quarter ended March 31, 2026 while entering into a planned acquisition by Biogen. Total revenue rose to $268.3 million from $166.8 million a year earlier, driven by $150.7 million in SYFOVRE sales, $41.3 million in EMPAVELI sales and $76.3 million in licensing and other revenue, including $55.0 million from Sobi milestones tied to European approvals.
The company generated net income of $18.7 million, or $0.15 per diluted share, compared with a net loss of $92.2 million, or $(0.74) per share, in the prior-year quarter. Cash and cash equivalents were $405.2 million, with $93.9 million of convertible notes and a $375.0 million term loan outstanding.
Biogen has agreed to acquire Apellis through a tender offer at $41.00 per share in cash plus one non-transferable contingent value right per share, which may pay up to an additional $4.00 in cash if specified SYFOVRE net sales milestones between 2027 and 2031 are achieved. Apellis believes its current cash and anticipated EMPAVELI and SYFOVRE sales will fund operations and capital needs for at least 12 months from the financial statement issuance date.
Apellis Pharmaceuticals, Inc. reported that its compensation committee approved an amendment and restatement of the Apellis Pharmaceuticals, Inc. Executive Separation Benefits and Retention Plan in connection with its previously announced Agreement and Plan of Merger with Biogen Inc. and Aspen Purchaser Sub, Inc.
The amended and restated Executive Separation Benefits and Retention Plan will become effective on, and is subject to the occurrence of, the Closing Date as defined in the Merger Agreement. The filing indicates this change is part of the broader transaction structure related to the planned merger.
Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a bona fide gift of 900 shares of common stock. The shares were transferred at no price as a charitable contribution. After this gift, she directly holds 86,525 shares, indicating she retains a substantial equity stake in the company.
Apellis Pharmaceuticals filed an amended annual report to add the full Part III disclosures that were originally expected to come from its proxy statement. The amendment does not change prior financial statements.
The filing describes a nine‑member classified board, with directors grouped into three staggered classes and removal only for cause with a 75% stockholder vote. It outlines four key committees—audit, compensation, compliance, and nominating and corporate governance—and their 2025 meeting activity, risk oversight roles, and independence determinations.
Apellis details a pay‑for‑performance executive compensation program combining salary, annual cash incentives and equity. For 2025, most executives earned 105% of target bonuses, while the CEO accepted 52.5% of target. Long‑term incentives shifted heavily to performance stock units tied to relative total shareholder return, alongside time‑based RSUs and a supplemental PSU/option program. The amendment also highlights strong 2025 say‑on‑pay support of over 94.8%, stock ownership guidelines, and an updated Dodd‑Frank–compliant recoupment policy.
Apellis Pharmaceuticals Chief Financial Officer Timothy Eugene Sullivan reported two bona fide gift transfers of common stock. On April 17, 2026, he gifted a total of 22,192 shares, including 11,096 shares transferred to The Timothy E Sullivan Irrevocable Trust of 2023.
After these gifts, the filing shows 71,492 shares held indirectly through the irrevocable trust and 140,945 shares held directly. The footnote states he disclaims beneficial ownership of shares held by the trust except to the extent of his pecuniary interest.
Apellis Pharmaceuticals, Inc. recommends that its stockholders accept the tender offer from Biogen to acquire all outstanding common shares for $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share that can pay up to $4.00 upon achievement of specified sales milestones. Apellis reports 128,007,815 Shares issued and outstanding as of April 9, 2026. The Apellis Board unanimously determined the offer is fair, approved the merger agreement and related CVR agreement, and recommends tendering; certain directors, executives and Morningside (support stockholders) agreed to tender and together hold approximately 14% of outstanding Shares. The offer initially expires one minute after 11:59 p.m. Eastern Time on May 13, 2026, and the merger will be effected by a tender offer followed by a Section 251(h) merger if conditions are met.
Biogen Inc. launches a tender offer to acquire Apellis Pharmaceuticals for $41.00 per share plus a contingent value right. Purchaser Aspen Purchaser Sub, a Biogen subsidiary, offers $41.00 in cash per Apellis share and one non-transferable contingent value right per share for up to an aggregate $4.00 upon specified milestones under a Contingent Value Rights Agreement, each subject to the terms of the Offer to Purchase. Apellis had 128,007,815 shares outstanding as of April 9, 2026, with additional potential dilution from convertible notes of $93,897,000 (convertible at 25.3405 shares per $1,000) and awarded equity awards described in the filing. The offer and the Merger Agreement govern the transaction; the Offer to Purchase, Letter of Transmittal, and merger documents are incorporated by reference.
Apellis Pharmaceuticals director Stephanie Monaghan O'Brien reported an internal share restructuring involving her spouse's holdings. A total of 5,750 shares of Common Stock were distributed from a trust to an account held directly by her spouse, and her beneficial ownership is unchanged. Following this, she reports 25,666 shares held directly and 5,750 shares held indirectly through her spouse.